The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis.
<h4>Background</h4>\Anticoagulation is used for stroke prophylaxis in non-valvular atrial fibrillation, amongst other by use of the vitamin K antagonist, warfarin. Quality in warfarin therapy is often summarized by the time patients spend within the therapeutic range (percent time in the...
Saved in:
| Main Authors: | Anne Sig Vestergaard, Flemming Skjøth, Torben Bjerregaard Larsen, Lars Holger Ehlers |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0188482 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TIME IN THERAPEUTIC RANGE (TTR) IN ATRIAL FIBRILLATION WITH WARFARIN THERAPY IN SEMARANG, INDONESIA
by: Della Dafina Sekarsari, et al.
Published: (2021-10-01) -
The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01) -
Modern warfarin- dosing algorithms in patients with atrial fibrillation
by: M. Yu. Kolesnyk, et al.
Published: (2015-12-01) -
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
by: Mette Søgaard, et al.
Published: (2019-03-01) -
Comparison between DOACs and warfarin for left atrial thrombus in atrial fibrillation patients
by: Akihiro Sunaga, et al.
Published: (2025-08-01)